Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research

Nicola Silvestris; Gennaro Ciliberto; Paolo De Paoli; Giovanni Apolone; Maria Luisa Lavitrano; Marco A Pierotti; Giorgio Stanta; On the behalf of the “dynamic medicine OECI group”

doi:10.1186/s13046-017-0598-x

Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research

Nicola Silvestris, Gennaro Ciliberto, Paolo De Paoli, Giovanni Apolone, Maria Luisa Lavitrano, Marco A Pierotti, Giorgio Stanta, On the behalf of the “dynamic medicine OECI group”

Research output: Contribution to journal › Review article › peer-review

Abstract

The increasing use of genomics to define the pattern of actionable mutations and to test and validate new therapies for individual cancer patients, and the growing application of liquid biopsy to dynamically track tumor evolution and to adapt molecularly targeted therapy according to the emergence of tumor clonal variants is shaping modern medical oncology., In order to better describe this new therapeutic paradigm we propose the term "Liquid dynamic medicine" in the place of "Personalized or Precision medicine". Clinical validation of the "Liquid dynamic medicine" approach is best captured by N-of-1 trials where each patient acts as tester and control of truly personalized therapies.

Original language	English
Pages (from-to)	128
Journal	Journal of Experimental and Clinical Cancer Research
Volume	36
Issue number	1
DOIs	https://doi.org/10.1186/s13046-017-0598-x
Publication status	Published - Sept 13 2017

Keywords

Journal Article
Review

Access to Document

10.1186/s13046-017-0598-x

Cite this

Silvestris, N., Ciliberto, G., De Paoli, P., Apolone, G., Lavitrano, M. L., Pierotti, M. A., Stanta, G., & On the behalf of the “dynamic medicine OECI group” (2017). Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research. Journal of Experimental and Clinical Cancer Research, 36(1), 128. https://doi.org/10.1186/s13046-017-0598-x

Silvestris, N , Ciliberto, G, De Paoli, P, Apolone, G, Lavitrano, ML, Pierotti, MA, Stanta, G & On the behalf of the “dynamic medicine OECI group” 2017, 'Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research', Journal of Experimental and Clinical Cancer Research, vol. 36, no. 1, pp. 128. https://doi.org/10.1186/s13046-017-0598-x

@article{3b55f432b03743c3ab8504e272656903,

title = "Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research",

abstract = "The increasing use of genomics to define the pattern of actionable mutations and to test and validate new therapies for individual cancer patients, and the growing application of liquid biopsy to dynamically track tumor evolution and to adapt molecularly targeted therapy according to the emergence of tumor clonal variants is shaping modern medical oncology., In order to better describe this new therapeutic paradigm we propose the term {"}Liquid dynamic medicine{"} in the place of {"}Personalized or Precision medicine{"}. Clinical validation of the {"}Liquid dynamic medicine{"} approach is best captured by N-of-1 trials where each patient acts as tester and control of truly personalized therapies.",

keywords = "Journal Article, Review",

author = "Nicola Silvestris and Gennaro Ciliberto and {De Paoli}, Paolo and Giovanni Apolone and Lavitrano, {Maria Luisa} and Pierotti, {Marco A} and Giorgio Stanta and {On the behalf of the “dynamic medicine OECI group”}",

year = "2017",

month = sep,

day = "13",

doi = "10.1186/s13046-017-0598-x",

language = "English",

volume = "36",

pages = "128",

journal = "Journal of Experimental and Clinical Cancer Research",

issn = "0392-9078",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Liquid dynamic medicine and N-of-1 clinical trials

T2 - a change of perspective in oncology research

AU - Silvestris, Nicola

AU - Ciliberto, Gennaro

AU - De Paoli, Paolo

AU - Apolone, Giovanni

AU - Lavitrano, Maria Luisa

AU - Pierotti, Marco A

AU - Stanta, Giorgio

AU - On the behalf of the “dynamic medicine OECI group”

PY - 2017/9/13

Y1 - 2017/9/13

N2 - The increasing use of genomics to define the pattern of actionable mutations and to test and validate new therapies for individual cancer patients, and the growing application of liquid biopsy to dynamically track tumor evolution and to adapt molecularly targeted therapy according to the emergence of tumor clonal variants is shaping modern medical oncology., In order to better describe this new therapeutic paradigm we propose the term "Liquid dynamic medicine" in the place of "Personalized or Precision medicine". Clinical validation of the "Liquid dynamic medicine" approach is best captured by N-of-1 trials where each patient acts as tester and control of truly personalized therapies.

AB - The increasing use of genomics to define the pattern of actionable mutations and to test and validate new therapies for individual cancer patients, and the growing application of liquid biopsy to dynamically track tumor evolution and to adapt molecularly targeted therapy according to the emergence of tumor clonal variants is shaping modern medical oncology., In order to better describe this new therapeutic paradigm we propose the term "Liquid dynamic medicine" in the place of "Personalized or Precision medicine". Clinical validation of the "Liquid dynamic medicine" approach is best captured by N-of-1 trials where each patient acts as tester and control of truly personalized therapies.

KW - Journal Article

KW - Review

U2 - 10.1186/s13046-017-0598-x

DO - 10.1186/s13046-017-0598-x

M3 - Review article

C2 - 28903768

SN - 0392-9078

VL - 36

SP - 128

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

IS - 1

ER -

Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research

Abstract

Keywords

Access to Document

Fingerprint

Cite this